Novartis | NOVN - Selling And Administration Expenses

Stock Price
127.76
Daily Change
-0.22 -0.17%
Monthly
10.25%
Yearly
26.85%
Q1 Forecast
123.39

Novartis reported $3.31B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alcon AG USD 865M 5M Sep/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Autolus Therapeutics Ltd USD 27.96M 1.58M Jun/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Fresenius EUR 676M 64M Sep/2025
Fresenius Medical Care EUR 705.44M 86.56M Sep/2025
Galapagos EUR 34.55M 3.88M Sep/2025
Genmab DKK 144M 18M Jun/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 284.99M 2.24M Sep/2025
Hikma Pharmaceutical USD 139M 149M Jun/2025
J&J USD 6.75B 831M Dec/2025
Merck EUR 1.46B 16M Sep/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Orion EUR 110.7M 26.1M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Philips EUR 1.31B 127M Dec/2025
Recordati EUR 171.38M 15.6M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.29B 221M Dec/2024